Data on the modulatory effects of a single bolus dexamethasone on the surface marker expression of various leucocyte subsets

Data in Brief

R. Taylor¹  S. Wallace²  C.R. Bain³  D.F. Draxler⁴  R.L. Medcalf⁵  O. Gouldthorpe⁶  P.S. Myles⁶  K. Bozaoglu⁶  T.B. Corcoran⁷ 

[1] Bern Center for Precision Medicine, Bern, Switzerland;Corresponding author.;Department of Cardiology, University hospital of Bern, Bern, Switzerland;Australian Centre for Blood Diseases, Monash University, Melbourne, VIC, Australia;Department of Anaesthesia and Pain Medicine, Royal Perth Hospital, University of Western Australia, Perth, WA, Australia and Monash University, Melbourne, VIC, Australia;Department of Anaesthesiology and Perioperative Medicine, The Alfred Hospital and Monash University, Melbourne, VIC, Australia;Genomics and Systems Biology Laboratory, Baker IDI Heart and Diabetes Institute Victoria, Melbourne, VIC, Australia;

关键词: Dexamethasone;    Glucocorticoids;    Immune response;    Inflammation;    Flowcytometry;    Leukocytes;   

DOI  :  

来源: DOAJ

【 摘 要 】

Dexamethasone is frequently administered to surgical patients for anti-emetic prophylaxis. We have examined the immunomodulatory effects of a single bolus of dexamethasone on circulating peripheral blood mononuclear cells (PBMCs) in the same 10 healthy male volunteers, previously used in our investigation on early in vivo effects of a single anti-emetic dose of dexamethasone on innate immune cell gene expression and activation [1]. Blood samples were drawn at baseline, 2 h, 4 h and 24 h. Immune cell phenotypes were examined with flow cytometry. In this data article the expression strength of markers involved in immune activation and immunosuppression as well as maturation, migration, cell death and responsiveness to signalling on monocyte and cDC subsets, as well as NK cells, CD4+ and CD8+ T cells and regulatory T cells (Treg) are presented. These data improve our understanding of the immunomodulatory effects of the glucocorticoid dexamethasone in-vivo, which may be important for the optimisation of treatment regimens as well as the evaluation of new indications for glucocorticoid treatment.

【 授权许可】

Unknown